Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes
April 05, 2021 07:00 ET | Source: Renalytix AI plc. Renalytix AI plc. New York, New York, UNITED STATES
NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted progressive kidney function decline and kidney failure in a multi-center, diverse cohort of 1,146 type 2 diabetes patients with early-stage (stages 1, 2, and 3) kidney disease versus the current standard of care. The results of the study, which is the second peer-reviewed clinical validation study on KidneyIntelX, have been published in
COVID-19 infections on the rise in the Bay Area, following national trend
FacebookTwitterEmail
1of2
Nurse Angelica Juarez (right) provides vaccination information to Gladys Sonchonchex as she visits the Southeast Health Center vaccination tent in San Francisco with her three children.Lea Suzuki / The ChronicleShow MoreShow Less
2of2
Suping She (right) assists David Johns in the line for vaccination at the Southeast Health Center in San Francisco.Lea Suzuki / The ChronicleShow MoreShow Less
Coronavirus infections trended up in the Bay Area for the week ending Friday, with the average number of daily new cases at 475, up 8.7% from the prior week ending March 26.